利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.016 秒)

    CHROMATOGRAPHY BASED PURIFICATION STRATEGIES FOR MEASLES SCAFFOLD BASED VIRUSES
    3.
    发明公开
    CHROMATOGRAPHY BASED PURIFICATION STRATEGIES FOR MEASLES SCAFFOLD BASED VIRUSES 审中-公开
    基于色谱的基于脚手架的病毒净化策略

    公开(公告)号：EP3184119A1

    公开(公告)日：2017-06-28

    申请号：EP15202480.8

    申请日：2015-12-23

    申请人： Themis Bioscience GmbH

    发明人： Müllner, Matthias ,  Tauber, Erich ,  Csar, Patrick ,  Irmler, Angelika ,  Ramsauer, Katrin ,  SCHRAUF, Sabrina

    IPC分类号： A61K39/165 ,  C12N7/02

    CPC分类号： C12N15/86 ,  A61K39/12 ,  C12N2760/18434 ,  C12N2760/18443 ,  C12N2770/24121 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2800/22 ,  C12N2840/105 ,  Y02A50/392

    摘要： The present invention provides purification strategies for sterically demanding, i.e. large and pleomorphic, infectious virus particles or VLPs derived therefrom having a measles virus scaffold to yield fractions or compositions with a significantly reduced content of contaminating host cell DNA and a reduced content of further process-related impurities. Further provided are methods of propagating and purifying infectious virus particles having a measles virus scaffold suitable to provide a preparation having a strongly reduced content of contaminating host cell DNA and a reduced content of further process-related impurities. In addition, immunogenic and vaccine compositions based on the above methods are provided. Finally, there are provided immunogenic or vaccine compositions produced by the disclosed methods, which are suitable for use in immunogenic or prophylactic vaccination treatment of a subject in need thereof.

    摘要翻译： 本发明提供了空间需求即大和多形感染性病毒颗粒或由其衍生的具有麻疹病毒支架的VLP的纯化策略，以产生具有显着降低的污染宿主细胞DNA含量的组分或组合物， 相关的杂质。 进一步提供了繁殖和纯化具有麻疹病毒支架的感染性病毒颗粒的方法，所述感染性病毒颗粒适于提供具有大大降低的污染性宿主细胞DNA含量和降低的其他过程相关杂质含量的制剂。 另外，提供了基于上述方法的免疫原性和疫苗组合物。 最后，提供了通过所公开的方法产生的免疫原性或疫苗组合物，其适用于有需要的受试者的免疫原性或预防性疫苗接种治疗。

    CO-STIMULATORY 4-1BBL ECTODOMAIN POLYPEPTIDES FOR IMMUNOMODULATION
    5.
    发明公开
    CO-STIMULATORY 4-1BBL ECTODOMAIN POLYPEPTIDES FOR IMMUNOMODULATION 审中-公开

    公开(公告)号：EP3957650A1

    公开(公告)日：2022-02-23

    申请号：EP20191286.2

    申请日：2020-08-17

    申请人： Themis Bioscience GmbH

    发明人： STRITZKER, Jochen ,  STEINBERGER, Peter ,  LUPINEK, Daniela ,  DE SOUSA LINHARES, Annika

    IPC分类号： C07K14/525 ,  C07K14/78 ,  A61K35/12

    摘要： The present invention generally relates to the field of immunomodulation and provides various costimulatory polypeptides comprising at least one 4-1BBL ectodomain comprising a minimal TNF Homology Domain. Further provided are vectors and oncolytic viruses expressing the 4-1BBL ectodomain and methods for producing the same. Additionally provided are methods and uses for obtaining and optionally purifying the inherently oligomerizing 4-1 BBL ectodomain polypeptides and associated oncolytic viruses for highly targeted cancer treatment, including the treatment of tumors. Finally, there are provided kits and uses of the polypeptides and vectors as disclosed.

    RECOMBINANT ZIKA VACCINES
    9.
    发明公开
    RECOMBINANT ZIKA VACCINES 审中-公开

    公开(公告)号：EP3903814A1

    公开(公告)日：2021-11-03

    申请号：EP21165273.0

    申请日：2016-12-23

    申请人： Themis Bioscience GmbH

    发明人： TAUBER, Erich ,  SCHRAUF, Sabrina ,  MÜLLNER, Matthias ,  RAMSAUER, Katrin ,  IRMLER, Angelika ,  CSAR, Patrick

    IPC分类号： A61K39/12 ,  C07K14/005

    摘要： The present invention relates to nucleic acid molecules building the basis for immunogenic or vaccine compositions for use in a method of preventing or treating a Zika virus disease in a subject, wherein the at least one nucleic acid molecule comprises at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment or variant thereof. Further provided are recombinant chimeric viruses encoding and/or comprising selected antigens from a Zika virus. The sequences encoding at least one Zika virus antigen suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition to provide an immunogenic composition with a low level of process- or product-related impurities.